PRAM9

PRAM9 is an investigational drug evaluated in clinical trials as a subcutaneous injection for diabetes management. It appears to be a novel formulation or analog related to pramlintide, an amylin analog used as an adjunct treatment with insulin in diabetes. In at least one phase 2 clinical trial, PRAM9 was compared directly with regular insulin and the combination of regular insulin plus pramlintide, suggesting it may be designed to improve glycemic control by mimicking or enhancing the effects of endogenous amylin when administered alongside insulin therapy[1][2]. The precise molecular structure, mechanism of action details, and developer information are not publicly disclosed.